The biotech sector experienced one of its most intense dealmaking periods of 2025 during November 10-15, with over $25 billion in total transaction value across M&A, licensing, and venture financing. Eli Lilly emerged as the week's most aggressive dealmaker with three partnerships totaling $3.2

Introduction: Raising Capital for Defense In the biotech industry's recent downturn, many companies have faced plummeting valuations – over 220 Nasdaq-listed biotechs traded below their net cash by late 2023. Desperate to fund R&D without diluting shareholders at rock-bottom prices, these firms increasingly turned to

Executive Summary Royalty Pharma (Nasdaq: RPRX) represents a paradox in modern pharmaceutical finance: a company that has simultaneously constructed formidable competitive moats while facing structural vulnerabilities that mainstream analysis consistently underestimates. The firm commands approximately 50% market share in biopharma royalty funding since 2020—roughly four times its nearest competitor—

With a name like Braveheart, this San Francisco-based biotech is showing plenty of heart (and courage) as it launches into the cardiovascular arena. In fact, the company just emerged in November 2025 with a formidable $185 million Series A war chest to tackle hypertrophic cardiomyopathy (HCM). (No word on

A New Axis of Royalty Flows China's biotech industry has become an increasingly vital node in global pharmaceutical value chains. Chinese-origin drugs are now out-licensed globally at scale, while Western firms aggressively seek to penetrate China's market via regional deals. These relationships generate complex,

A scientist in a university lab toils over a breakthrough therapy. Years later, that discovery becomes a best-selling drug, delivering a steady stream of royalty income to the university. Once regarded simply as a happy windfall, these royalty streams are now treated as strategic financial assets. Universities across the

Introduction: The Perfect Storm of Regulatory and Pricing Uncertainty The pharmaceutical royalty market is experiencing an unprecedented convergence of regulatory and reimbursement disruptions that fundamentally challenge traditional valuation methodologies. For royalty investors who purchase rights to future drug revenues, the landscape has shifted from predictable, linear risk models to a

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

On 19 November, as the Jefferies London Healthcare Conference closes for the day, a different conversation begins. Registration for our evening session has passed 50 attendees, with more capital than companies in the room. The panel brings relevant experience to the table. Tony Hickson, Chief Business Officer at Cancer Research

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may